Table 1 The relationship between miR-21 levels and clinicopathological characteristics of breast cancer patients
From: microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1
Patients frequency(%) | miR-21 expression | P -value | ||
|---|---|---|---|---|
Low expression | High expression | |||
|  | Total N = 252 | N = 126 | N = 126 |  |
Age (years) | ||||
 ≤ 50 | 75 (29.7%) | 35 (27.8%) | 40 (31.7%) | 0.086 |
  > 50 | 177 (70.3%) | 91 (72.2%) | 86 (68.3%) |  |
Tumor size (cm) | ||||
  ≤ 3.0 | 142 (56.3%) | 82 (65%) | 60 (47.6%) | 0.002 |
  > 3.0 | 100 (43.7%) | 44 (35%) | 66 (52.4%) |  |
LN metastasis | ||||
 Negative | 103 (41%) | 63 (50%) | 40 (31.7%) | 0.001 |
 Positive | 149 (59%) | 63 (50%) | 86 (68.3%) |  |
TNM stage | ||||
 I | 51 (20.2%) | 46 (36.5%) | 5 (4%) | IvsII < 0.005 |
 II | 11 (46.8%) | 63 (50%) | 55 (43.6%) | IIvsIII < 0.001 |
 III | 83 (33%) | 17 (13.5%) | 66 (40%) | IvsIII < 0.001 |
PR expression | ||||
 Negative | 66 (26.2%) | 30 (23.8%) | 36 (28.6%) | 0.07 |
 Positive | 186 (73.8%) | 96 (76.2%) | 90 (71.4%) |  |
ER expression | ||||
 Negative | 68 (27%) | 31 (24.6%) | 37 (29.4%) | 0.07 |
 Positive | 184 (73%) | 95 (75.3%) | 89 (70.6%) |  |
HER-2 expression | ||||
 Negative | 78 (31%) | 44 (34.9%) | 34 (27%) | 0.029 |
 Positive | 174 (69%) | 82 (65.1%) | 92 (73%) |  |